Cell-specific delivery of a chemotherapeutic to lung cancer cells

Center for Biomedical Inventions and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9185, USA.
Journal of the American Chemical Society (Impact Factor: 11.44). 01/2005; 126(48):15656-7. DOI: 10.1021/ja0446496
Source: PubMed

ABSTRACT We report that lung cancer-targeting peptides isolated from a peptide library can be used to deliver an active chemotherapeutic in a cell-specific fashion. The peptides were removed from the context of the phage and placed on a pegylated tetrameric scaffold. The tetrameric peptides were shown to block uptake of their cognate phage. The tetrameric peptides were coupled to doxorubicin, and their cytotoxicity against a panel of different cell lines was tested. Our data demonstrate that these targeting peptides can deliver an active anticancer agent in a cell-specific fashion, resulting in an increase of the therapeutic index of the targeted drug compared to systemic delivery. The efficacy of the peptide conjugate correlates to the affinity of the targeting peptide for a particular cell line. As such, we have demonstrated that cell-specific targeted drugs can be synthesized, even when the cell surface target is unknown.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Integrins, a family of cell adhesion molecules composed of α and β heterodimeric subunits, are involved in a wide range of cell-extracellular matrix and cell-cell interactions. The study of integrin family members as targets for molecular imaging and therapy has been generally limited with the exception of integrin αvβ3. vβ6, a member of the integrin family, is expressed at low or undetectable levels in normal tissues, but is widely upregulated during many pathological and physiological processes, especially cancer and fibrosis, making it a promising target for molecular imaging. Noninvasive and quantitative imaging of integrin vβ6 expression would be very useful for disease diagnosis, treatment monitoring, and prognosis assessment. Although various molecular probes have been developed for positron emission tomography and single-photon emission computed tomography imaging of integrin vβ6 expression in preclinical animal models, further research efforts are required to optimize integrin vβ6-targeting probes for future potential clinical applications in the fields of oncology and beyond.
    American Journal of Nuclear Medicine and Molecular Imaging 01/2014; 4(4):333-45. · 3.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Integrin αvβ6, a member of the integrin family, is specifically expressed in many malignancies but not in normal organs. Overexpression of integrin αvβ6 is usually correlated with malignant potential and poor prognosis. In this study, we describe the synthesis and evaluation of a (99m)Tc-labeled integrin αvβ6-targeting peptide as a SPECT radiotracer for the in vivo imaging of integrin αvβ6 expression. An integrin αvβ6-targeting peptide (denoted as the HK peptide) was conjugated with 6-hydrazinonicotinyl (HYNIC) and radiolabeled with (99m)Tc using tricine and TPPTS (trisodium triphenylphosphine-3,3',3″-trisulfonate) as coligands. The in vitro and in vivo characteristics of (99m)Tc-HYNIC(tricine)(TPPTS)-HK ((99m)Tc-HHK) were investigated in BxPC-3 (integrin αvβ6-positive) and HEK293 (integrin αvβ6-negative) models. The ability of (99m)Tc-HHK to detect liver metastasis of pancreatic cancer was evaluated using small-animal SPECT/CT. (99m)Tc-HHK showed high integrin αvβ6-binding specificity both in vitro and in vivo. (99m)Tc-HHK was cleared rapidly from the blood and normal organs except for the kidneys. The highest uptake (0.88 ± 0.12 percentage injected dose per gram) of (99m)Tc-HHK in BxPC-3 tumors was observed at 0.5 h after injection. High-contrast images of integrin αvβ6-positive tumors were obtained using (99m)Tc-HHK. The minimum nonspecific activity accumulation in normal liver tissues rendered high-quality SPECT/CT images of metastatic lesions. (99m)Tc-HHK is a promising SPECT radiotracer for the noninvasive imaging of integrin αvβ6 expression in vivo. SPECT/CT with (99m)Tc-HHK could provide an effective approach for the noninvasive detection of primary and metastatic lesions of integrin αvβ6-positive tumors.
    Journal of Nuclear Medicine 04/2014; 55(6). DOI:10.2967/jnumed.113.132969 · 5.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The solid-phase synthesis, structural characterization, and biological evaluation of a small library of cancer-targeting peptides have been determined in HepG2 hepatoblastoma cells. These peptides are based on the highly specific Pep42 motif, which has been shown to target the glucose-regulated protein 78 receptors overexpressed and exclusively localized on the cell surface of tumors. In this study, Pep42 was designed to contain varying lengths (3-12) of poly(arginine) sequences to assess their influence on peptide structure and biology. Peptides were effectively synthesized by 9-fluorenylmethoxycarbonyl-based solid-phase peptide synthesis, in which the use of a poly(ethylene glycol) resin provided good yields (14-46%) and crude purities >95% as analyzed by liquid chromatography-mass spectrometry. Peptide structure and biophysical properties were investigated using circular dichroism spectroscopy. Interestingly, peptides displayed secondary structures that were contingent on solvent and length of the poly(arginine) sequences. Peptides exhibited helical and turn conformations, while retaining significant thermal stability. Structure-activity relationship studies conducted by flow cytometry and confocal microscopy revealed that the poly(arginine) derived Pep42 sequences maintained glucose-regulated protein 78 binding on HepG2 cells while exhibiting cell translocation activity that was contingent on the length of the poly(arginine) strand. In single dose (0.15 mM) and dose-response (0-1.5 mM) cell viability assays, peptides were found to be nontoxic in human HepG2 liver cancer cells, illustrating their potential as safe cancer-targeting delivery agents. Copyright © 2014 European Peptide Society and John Wiley & Sons, Ltd.
    Journal of Peptide Science 09/2014; 20(9). DOI:10.1002/psc.2665 · 1.86 Impact Factor

Full-text (2 Sources)

Available from
May 23, 2014